VQ Biomedical

VQ Biomedical develops innovative medical devices, focusing on intravascular oxygenation technology to enhance treatment for patients with respiratory failure. VQ Biomedical designs intravascular oxygenation catheters that deliver supplemental oxygen into the bloodstream, improving gas exchange for patients with respiratory complications. The company was founded by individuals with prior experience in medical technology, although specific names are not disclosed. Based in the US, VQ Biomedical has secured a total of 2 deals, notably raising USD 1.

65 mn in Seed funding on March 27, 2025, from Duke Capital Partners, Harbright Ventures, Medical Technology Venture Partners, and Wolfpack Investor Network, contributing to an overall raised amount of USD 1. 65 mn. VQ Biomedical specializes in a groundbreaking intravascular oxygenation catheter designed to deliver supplemental oxygen directly into the bloodstream of hospitalized patients suffering from respiratory failure. This innovative technology addresses a critical gap in current medical treatments by providing effective gas exchange independently of injured lungs, thus allowing them to rest and heal.

Unlike traditional mechanical ventilation and VV-ECMO systems, the catheter operates without external blood circulation, minimizing further patient injury. Healthcare providers and specialists in critical care, particularly in hospitals across North America, Europe, and Asia, are the primary users of this technology, which targets severe respiratory conditions such as ARDS to enhance patient outcomes significantly. VQ Biomedical's revenue model centers around business-to-business (B2B) transactions with healthcare facilities, including hospitals and specialized medical centers. The company generates revenue through direct sales of its oxygenation catheters, with potential partnerships for distribution and integration into existing healthcare systems.

The pricing structure reflects the innovative nature of the technology and the clinical benefits it offers, although specific pricing details are proprietary. The firm’s expected revenue streams are supported by confirmed orders from health systems and growing interest from healthcare providers exploring alternatives to current respiratory therapies, alongside potential partnerships with institutions for clinical trials and product evaluation. In March 2025, VQ Biomedical raised USD 1. 65 mn in Seed funding, co-led by new investors Wolfpack Investor Network, Harbright Ventures, and Duke Capital Partners.

This funding will be utilized to expand the team and advance their intravascular oxygenation device toward clinical trials within the next few years. The company is focused on designing upcoming products that will further improve respiratory therapies and plans to expand into new markets, particularly targeting Europe and Asia by 2026.